Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 4/27/26 | Mundipharma | Rezzayo for Fungal Infections - Systemic | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/27/26 | Mundipharma | Rezzayo for Candidiasis | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/27/26 | Compass Therapeutics (CMPX) | tovecimig for Biliary Tract Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/23/26 | Novo Nordisk (NVO) | Rybelsus for Diabetes Mellitus, Type II | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/23/26 | AbbVie (ABBV) | Trenibote for Wrinkles | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 06/30/2022 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 06/30/2022 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 06/30/2022 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 10/22/2023 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 10/22/2023 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |